Cogent Biosciences Inc

Insider buying signals strong confidence in Cogent’s future, with director Ferrante acquiring 686 option shares to back its oncology pipeline and bezuclastinib FDA progress.

Fairmount’s March 31 move converts Cogent’s preferred to common, boosting its stake and signaling confidence in near‑term upside.

Fairmount sells 3.5 M Cogent Biosciences shares at $36.40, a near‑market tactical move that may reshape investor strategy and signals potential upside.